A new study investigated vaccine efficacy of a primary series and booster dose across multiple variants, including the BA.1 omicron variant, in SLE patients. This is one of the first studies on vaccine efficacy of a primary series and booster dose across multiple variants, including the BA.1 omicron variant, especially in an autoimmune disease patient cohort.
Read More »The Lancet recently conducted a literature review of antibody responses after COVID-19 vaccination in immunocompromised persons published between July 1, 2020, and September 27, 2021. Authors aggregated information from 23 studies with a total of 1722 persons who received an additional dose of a COVID-19 vaccine due to their immunocompromised status.
Read More »Last Friday, the CDC updated their vaccine guidance for immunocompromised persons. It is now recommended that persons 12+ who are immunocompromised receive a booster dose. “If you are eligible for an additional primary shot, you should get this done before you get a booster shot.”
Read More »A UK Health Security Agency technical briefing has reported that the new Omicron variant is able to evade antibodies from both vaccination and previous infection. Vaccine effectiveness was reportedly lower for Omicron than the Delta variant, with evidence of waning protection against symptomatic disease by 10 weeks after a booster dose.
Read More »